Eric M Reiman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2732512/publications.pdf

Version: 2024-02-01

324 papers	47,987 citations	1980 101 h-index	1974 206 g-index
356 all docs	356 docs citations	356 times ranked	39059 citing authors

#	Article	IF	Citations
1	A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 2613-2622.	1.9	4
2	Limitations of clinical trial sample size estimate by subtraction of two measurements. Statistics in Medicine, 2022, 41, 1137-1147.	0.8	2
3	Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care Program. American Journal of Geriatric Psychiatry, 2022, 30, 651-660.	0.6	4
4	Studying APOE É›4 Allele Dose Effects withÂa Univariate Morphometry Biomarker. Journal of Alzheimer's Disease, 2022, 85, 1233-1250.	1.2	1
5	Sex differences in cognitive resilience in preclinical autosomalâ€dominant Alzheimer's disease carriers and nonâ€carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimer's and Dementia, 2022, 18, 2272-2282.	0.4	10
6	APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study. Alzheimer's and Dementia, 2022, 18, 2518-2526.	0.4	19
7	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.4	13
8	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. Genome Medicine, 2022, 14, 27.	3.6	16
9	Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimerâ€™s disease. Brain Communications, 2022, 4, fcab293.	1.5	10
10	Genetic Evidence Supporting a Causal Role of Depression in Alzheimerâ€™s Disease. Biological Psychiatry, 2022, 92, 25-33.	0.7	18
11	White matter hyperintensities are a prominent feature of autosomalÂdominant Alzheimerâ€™s disease that emerge prior to dementia. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
12	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimerâ€™s dementia. Acta Neuropathologica, 2022, 144, 589-601.	3.9	32
13	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. Medical Image Analysis, 2021, 67, 101877.	7.0	10
14	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
15	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimerâ€™s disease-causing Presenilin-1 E280A mutation carriers. NeuroImage: Clinical, 2021, 31, 102749.	1.4	8
16	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimerâ€™s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimer's Research and Therapy, 2021, 13, 27.	3.0	34
17	Cortical thickness across the lifespan in a Colombian cohort with autosomalâ€dominant Alzheimer's disease: A crossâ€sectional study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12233.	1.2	2
18	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.5	149

#	Article	IF	Citations
19	Genetic control of the human brain proteome. American Journal of Human Genetics, 2021, 108, 400-410.	2.6	52
20	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
21	Brain proteome-wide association study implicates novel proteins in depression pathogenesis. Nature Neuroscience, 2021, 24, 810-817.	7.1	85
22	Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding. Journal of Alzheimer's Disease, 2021, 81, 209-220.	1.2	6
23	Predicting future cognitive decline with hyperbolic stochastic coding. Medical Image Analysis, 2021, 70, 102009.	7.0	2
24	Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE É›3/É›4 Carriers. Journal of Alzheimer's Disease, 2021, 81, 339-354.	1.2	13
25	Soluble Pâ€tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90
26	Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. Aging, 2021, 13, 17097-17117.	1.4	9
27	Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort. JAMA Network Open, 2021, 4, e2121697.	2.8	3
28	Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. Advanced Science, 2021, 8, e2101462.	5.6	66
29	Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases. Frontiers in Neuroscience, 2021, 15, 669595.	1.4	15
30	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. Alzheimer's Research and Therapy, 2021, 13, 136.	3.0	30
31	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	5.8	43
32	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	4.9	65
33	Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares. Translational Psychiatry, 2021, 11, 473.	2.4	18
34	Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimerâ€™s disease pathogenesis. Nature Genetics, 2021, 53, 143-146.	9.4	158
35	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	2.8	19
36	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimerâ€™s amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	2.4	31

#	Article	IF	Citations
37	Predicting Tau accumulation in cerebral cortex with multivariate MRI morphometry measurements, sparse coding, and correntropy. , 2021, 12088, .		1
38	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.4	23
39	Longitudinal white matter and cognitive development in pediatric carriers of the apolipoprotein Îµ4 allele. NeuroImage, 2020, 222, 117243.	2.1	14
40	Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimerâ€™s Disease and Cognitive Decline. Journal of Alzheimer's Disease, 2020, 78, 721-734.	1.2	11
41	Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline. NeuroImage: Clinical, 2020, 27, 102338.	1.4	18
42	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
43	Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimerâ€™s Disease: Preliminary Findings from the Colombian Alzheimerâ€™s Prevention Initiative Biomarker Study. Journal of Alzheimer's Disease, 2020, 77, 1743-1753.	1.2	12
44	The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2. Alzheimer's and Dementia, 2020, 16, e041139.	0.4	1
45	Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after washâ€out. Alzheimer's and Dementia, 2020, 16, e041140.	0.4	4
46	The API Generation program: Umibecestat treatment and discontinuation effects on hippocampal and whole brain volumes in the overall population and amyloidâ€negative APOE4 homozygotes. Alzheimer's and Dementia, 2020, 16, e041142.	0.4	3
47	The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2. Alzheimer's and Dementia, 2020, 16, e041143.	0.4	2
48	Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimerâ€™s disease and implicate its dynamic role in disease progression. Clinical Epigenetics, 2020, 12, 189.	1.8	21
49	Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomalâ€Dominant Alzheimer's Disease Colombia Trial. Alzheimer's and Dementia, 2020, 16, 1023-1030.	0.4	15
50	Effects of LDL Cholesterol and Statin Use on Verbal Learning and Memory in Older Adults at Genetic Risk for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 75, 903-910.	1.2	4
51	Effect of ApoE isoforms on mitochondria in Alzheimer disease. Neurology, 2020, 94, e2404-e2411.	1.5	71
52	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	4.9	97
53	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology, 2020, 95, e1312-e1321.	1.5	7
54	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643

#	Article	IF	Citations
55	Exceptionally low likelihood of Alzheimerâ€™s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	5.8	246
56	APOE4 leads to bloodâ€“brain barrier dysfunction predicting cognitive decline. Nature, 2020, 581, 71-76.	13.7	705
57	Computing Univariate Neurodegenerative Biomarkers with Volumetric Optimal Transportation: A Pilot Study. Neuroinformatics, 2020, 18, 531-548.	1.5	3
58	Large-scale proteomic analysis of Alzheimerâ€™s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	15.2	547
59	Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimerâ€™s disease dementia. PLoS ONE, 2020, 15, e0231720.	1.1	27
60	Long-Term Physical Exercise and Mindfulness Practice in an Aging Population. Frontiers in Psychology, 2020, 11, 358.	1.1	11
61	Risk Factors for Alzheimerâ€™s Disease and Related Dementia Diagnoses in American Indians. Ethnicity and Disease, 2020, 30, 671-680.	1.0	11
62	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology, 2019, 76, 1219.	4.5	107
63	EDITORIAL: BLOOD TESTS FOR ALZHEIMERâ€™S DISEASE AND RELATED DISORDERS. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-2.	1.5	0
64	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	1.8	80
65	Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS ONE, 2019, 14, e0217566.	1.1	31
66	Applying surface-based hippocampal morphometry to study APOE-E4 allele dose effects in cognitively unimpaired subjects. NeuroImage: Clinical, 2019, 22, 101744.	1.4	40
67	Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. Nature Communications, 2019, 10, 1619.	5.8	144
68	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	13.9	165
69	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
70	GeneMatch: A novel recruitment registry using atâ€home APOE genotyping to enhance referrals to Alzheimer's prevention studies. Alzheimer's and Dementia, 2019, 15, 515-524.	0.4	38
71	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
72	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328

#	Article	IF	Citations
73	A concise and persistent feature to study brain restingâ€state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative. Human Brain Mapping, 2019, 40, 1062-1081.	1.9	26
74	Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 705-716.	1.8	27
75	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 548.	4.5	137
76	Long-term forgetting in preclinical Alzheimer's disease. Lancet Neurology, The, 2018, 17, 104-105.	4.9	4
77	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
78	Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimerâ€™s Disease Related Brain Regions. Journal of Alzheimer's Disease, 2018, 62, 833-840.	1.2	7
79	The Alzheimer's Prevention Initiative Autosomalâ€Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomalâ€dominant Alzheimer's disease, including a placeboâ€treated noncarrier cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 150-160.	1.8	107
80	Multiscale Analysis of Independent Alzheimerâ€™s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron, 2018, 99, 64-82.e7.	3.8	558
81	Hippocampus morphometry study on pathology-confirmed Alzheimer's disease patients with surface multivariate morphometry statistics. , 2018, 2018, 1555-1559.		17
82	Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET. Journal of Alzheimer's Disease, 2018, 63, 603-615.	1.2	12
83	Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 283-287.	1.8	4
84	The human brainome: network analysis identifies HSPA2 as a novel Alzheimerâ€™s disease target. Brain, 2018, 141, 2721-2739.	3.7	31
85	Left lateralized cerebral glucose metabolism declines in amyloid-Î² positive persons with mild cognitive impairment. NeuroImage: Clinical, 2018, 20, 286-296.	1.4	64
86	Peripheral apoE isoform levels in cognitively normal APOE Îµ3/Îµ4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimer's Research and Therapy, 2017, 9, 5.	3.0	29
87	Putting AD treatments and biomarkers to the test. Nature Reviews Neurology, 2017, 13, 74-76.	4.9	14
88	Prevalence, Patterns, and Predictors of Depression Treatment among Community-Dwelling Elderly Individuals with Dementia in the United States. American Journal of Geriatric Psychiatry, 2017, 25, 803-813.	0.6	16
89	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
90	Accelerating drug development for Alzheimer's disease through the use of data standards. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 273-283.	1.8	10

#	Article	IF	Citations
91	Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. Neurology, 2017, 89, 1464-1470.	1.5	23
92	Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer's, Parkinson's, control, and those at risk for developing Alzheimer's. Neurobiology of Aging, 2017, 58, 225-237.	1.5	15
93	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
94	The Colombian Alzheimer's Prevention Initiative (API) Registry. Alzheimer's and Dementia, 2017, 13, 602-605.	0.4	15
95	[ICâ€Pâ€041]: SAMPLE SIZES FOR 24â€MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€POSITIVE ADULTS. Alzheimer's and Dementia, 2017, 13, P36.	0.4	0
96	[O5â€“01â€“04]: SAMPLE SIZES FOR 24â€MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOIDâ€POSITIVE ADULTS. Alzheimer's and Dementia, 2017, 13, P1453.	0.4	0
97	Plasma Levels of AÎ²42 and Tau Identified Probable Alzheimerâ€™s Dementia: Findings in Two Cohorts. Frontiers in Aging Neuroscience, 2017, 9, 226.	1.7	85
98	APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Medicine, 2017, 14, e1002254.	3.9	110
99	Upper-Extremity Dual-Task Function: An Innovative Method to Assess Cognitive Impairment in Older Adults. Frontiers in Aging Neuroscience, 2016, 8, 167.	1.7	45
100	A Triple Network Connectivity Study of Large-Scale Brain Systems in Cognitively Normal APOE4 Carriers. Frontiers in Aging Neuroscience, 2016, 8, 231.	1.7	39
101	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	1.1	45
102	A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases. Alzheimer Disease and Associated Disorders, 2016, 30, 223-229.	0.6	15
103	The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 345-356.	1.2	56
104	Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene. International Psychogeriatrics, 2016, 28, 503-510.	0.6	15
105	F4â€03â€04: The Alzheimer's Prevention Initiative. Alzheimer's and Dementia, 2016, 12, P327.	0.4	1
106	What are we willing to accept for preventing Alzheimer's disease? â€“ Investigators' reply. Lancet Neurology, The, 2016, 15, 660-661.	4.9	1
107	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	1.5	53
108	Attack on amyloid-Î² protein. Nature, 2016, 537, 36-37.	13.7	42

#	Article	IF	Citations
109	Applying sparse coding to surface multivariate tensor-based morphometry to predict future cognitive decline. , 2016, 2016, 646-650.		25
110	Hyperbolic Space Sparse Coding with Its Application on Prediction of Alzheimerâ€™s Disease in Mild Cognitive Impairment. Lecture Notes in Computer Science, 2016, 9900, 326-334.	1.0	17
111	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimer's and Dementia, 2016, 12, 631-632.	0.4	26
112	Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 748-754.	0.9	82
113	Ketones block amyloid entry and improve cognition in an Alzheimer's model. Neurobiology of Aging, 2016, 39, 25-37.	1.5	107
114	Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2016, 73, 431.	4.5	69
115	CAPâ€”advancing the evaluation of preclinical Alzheimer disease treatments. Nature Reviews Neurology, 2016, 12, 56-61.	4.9	80
116	A potential role for the midbrain in integrating fatâ€free mass determined energy needs: An H₂¹⁵O PET study. Human Brain Mapping, 2015, 36, 2406-2415.	1.9	19
117	Improved Power for Characterizing Longitudinal Amyloid-Î² PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region. Journal of Nuclear Medicine, 2015, 56, 560-566.	2.8	122
118	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
119	Association of Pituitary Adenylate Cyclaseâ€“Activating Polypeptide With Cognitive Decline in Mild Cognitive Impairment Due to Alzheimer Disease. JAMA Neurology, 2015, 72, 333.	4.5	48
120	<scp>A</scp>rizona <scp>S</scp>tudy of <scp>A</scp>ging and <scp>N</scp>eurodegenerative <scp>D</scp>isorders and <scp>B</scp>rain and <scp>B</scp>ody <scp>D</scp>onation <scp>P</scp>rogram. Neuropathology, 2015, 35, 354-389.	0.7	336
121	PL-01-01: What will it take to end Alzheimer's?. , 2015, 11, P121-P122.		0
122	Disrupted Functional and Structural Networks in Cognitively Normal Elderly Subjects with the APOE Ɛ4 Allele. Neuropsychopharmacology, 2015, 40, 1181-1191.	2.8	60
123	Disrupted Frontoparietal Network Mediates White Matter Structure Dysfunction Associated with Cognitive Decline in Hypertension Patients. Journal of Neuroscience, 2015, 35, 10015-10024.	1.7	78
124	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's and Dementia, 2015, 11, 757-771.	0.4	199
125	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2015, 72, 912.	4.5	94
126	Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation. Neurology, 2015, 84, 206-208.	1.5	18

#	Article	IF	Citations
127	Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimer's and Dementia, 2015, 11, 994-1004.	0.4	58
128	Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred. JAMA Neurology, 2015, 72, 316.	4.5	145
129	Measurement of Longitudinal Î²-Amyloid Change with ¹⁸F-Florbetapir PET and Standardized Uptake Value Ratios. Journal of Nuclear Medicine, 2015, 56, 567-574.	2.8	273
130	Characterizing Apolipoprotein E Îµ4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal Î²-Amyloid Peptide Plaques. JAMA Neurology, 2015, 72, 1124.	4.5	78
131	Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiology of Aging, 2015, 36, 583-591.	1.5	156
132	Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry. NeuroImage, 2015, 104, 1-20.	2.1	42
133	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 101-109.	0.6	14
134	The Alzheimerâ€™s Prevention Initiative Composite Cognitive Test Score. Journal of Clinical Psychiatry, 2014, 75, 652-660.	1.1	75
135	Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e105784.	1.1	16
136	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
137	Pituitary adenylate cyclaseâ€“activating polypeptide is reduced in Alzheimer disease. Neurology, 2014, 82, 1724-1728.	1.5	53
138	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. PLoS Genetics, 2014, 10, e1004606.	1.5	305
139	Neuropathologic Heterogeneity Does Not Impair Florbetapir-Positron Emission Tomography Postmortem Correlates. Journal of Neuropathology and Experimental Neurology, 2014, 73, 72-80.	0.9	36
140	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
141	Pituitary adenylate cyclase-activating polypeptide protects against Î²-amyloid toxicity. Neurobiology of Aging, 2014, 35, 2064-2071.	1.5	97
142	The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 84-92.	0.4	55
143	Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiology of Aging, 2014, 35, 1386-1395.	1.5	116
144	Alzheimer's disease and other dementias: advances in 2013. Lancet Neurology, The, 2014, 13, 3-5.	4.9	29

#	Article	IF	Citations
145	Brain Differences in Infants at Differential Genetic Risk for Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 11.	4.5	221
146	Fibrillar amyloid correlates of preclinical cognitive decline. , 2014, 10, e1-e8.		15
147	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.5	391
148	An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 666-674.	0.4	110
149	Endpoints in Preclinical Alzheimerâ€™s Disease Trials. Journal of Clinical Psychiatry, 2014, 75, 661-662.	1.1	6
150	Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 2013, 9, 371-381.	4.9	125
151	Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology. JAMA Neurology, 2013, 70, 1150.	4.5	143
152	APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1007-1017.	1.5	63
153	Overfeeding Over 24 Hours Does Not Activate Brown Adipose Tissue in Humans. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1956-E1960.	1.8	39
154	Apolipoprotein E Îµ4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiology of Aging, 2013, 34, 1-12.	1.5	208
155	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 2013, 34, 822-831.	1.5	118
156	Polymorphism of brain derived neurotrophic factor influences Î² amyloid load in cognitively intact apolipoprotein E Îµ4 carriers. NeuroImage: Clinical, 2013, 2, 512-520.	1.4	47
157	O2-03-01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score. , 2013, 9, P320-P320.		0
158	Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology, 2013, 80, 1557-1564.	1.5	83
159	Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months. American Journal of Geriatric Psychiatry, 2013, 21, S136.	0.6	1
160	Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies. American Journal of Geriatric Psychiatry, 2013, 21, S138-S139.	0.6	0
161	Alzheimer's disease-related changes in regional spontaneous brain activity levels and inter-region interactions in the default mode network. Brain Research, 2013, 1509, 58-65.	1.1	14
162	A Genome-Wide Association Study of Depressive Symptoms. Biological Psychiatry, 2013, 73, 667-678.	0.7	149

#	Article	IF	Citations
163	Florbetapir (F18â€Aâ€45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer's and Dementia, 2013, 9, S72-83.	0.4	200
164	Fat-free body mass but not fat mass is associated with reduced gray matter volume of cortical brain regions implicated in autonomic and homeostatic regulation. NeuroImage, 2013, 64, 712-721.	2.1	45
165	Posterior Cingulate Glucose Metabolism, Hippocampal Glucose Metabolism, and Hippocampal Volume in Cognitively Normal, Late-Middle-Aged Persons at 3 Levels of Genetic Risk for Alzheimer Disease. JAMA Neurology, 2013, 70, 320.	4.5	123
166	Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients With Moderate to Severe Alzheimer Dementia. Journal of Clinical Psychopharmacology, 2013, 33, 636-642.	0.7	29
167	Initial Assessment of the Pathogenic Mechanisms of the Recently Identified Alzheimer Risk Loci. Annals of Human Genetics, 2013, 77, 85-105.	0.3	41
168	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 556-561.	0.9	44
169	Apolipoprotein E as a Î²-amyloid-independent factor in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 38.	3.0	48
170	Association between an Alzheimerâ€™s Disease-Related Index and APOE Îµ4 Gene Dose. PLoS ONE, 2013, 8, e67163.	1.1	13
171	Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome. , 2013, s7, 002.		7
172	Amyloid-Î² assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology, 2012, 79, 1636-1644.	1.5	206
173	Summary Metrics to Assess Alzheimer Diseaseâ€“Related Hypometabolic Pattern with ‹sup›18‹/sup›F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	2.8	79
174	A coding variant in CR1 interacts with APOE-É›4 to influence cognitive decline. Human Molecular Genetics, 2012, 21, 2377-2388.	1.4	90
175	Considerations in the Design of Clinical Trials for Cognitive Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67, 766-772.	1.7	14
176	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurology, The, 2012, 11, 1048-1056.	4.9	450
177	Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-Î² plaques: a prospective cohort study. Lancet Neurology, The, 2012, 11, 669-678.	4.9	674
178	Longitudinal modeling of cognitive aging and the ‹i›TOMM40‹/i› effect. Alzheimer's and Dementia, 2012, 8, 490-495.	0.4	61
179	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. Journal of Alzheimer's Disease, 2012, 33, S405-S416.	1.2	73
180	Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiology of Aging, 2012, 33, 827.e11-827.e19.	1.5	109

#	Article	IF	Citations
181	A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiology of Aging, 2012, 33, 1017.e1-1017.e15.	1.5	160
182	Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults. Neurobiology of Aging, 2012, 33, 2723-2732.	1.5	81
183	Florbetapir PET analysis of amyloid-Î² deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurology, The, 2012, 11, 1057-1065.	4.9	209
184	Brain imaging in the study of Alzheimer's disease. NeuroImage, 2012, 61, 505-516.	2.1	109
185	Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei â€" A combined MRI and H215O PET study. NeuroImage, 2012, 60, 592-600.	2.1	13
186	Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E Îµ4 gene dose in cognitively normal adults: A cross-validation study using voxel-based multi-modal partial least squares. NeuroImage, 2012, 60, 2316-2322.	2.1	36
187	Analysis of Copy Number Variation in Alzheimerâ€™s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals. PLoS ONE, 2012, 7, e50640.	1.1	49
188	Attentionâ€related networks in Alzheimer's disease: A resting functional MRI study. Human Brain Mapping, 2012, 33, 1076-1088.	1.9	110
189	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	3.3	55
190	Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. NeuroImage, 2011, 57, 5-14.	2.1	77
191	Large-scale directional connections among multi resting-state neural networks in human brain: A functional MRI and Bayesian network modeling study. NeuroImage, 2011, 56, 1035-1042.	2.1	49
192	Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEÎµ4 carriers. NeuroImage, 2011, 54, 1896-1902.	2.1	22
193	Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease. Archives of Neurology, 2011, 68, 1404.	4.9	310
194	Functional Links Between AÎ² Toxicity, Endocytic Trafficking, and Alzheimerâ€™s Disease Risk Factors in Yeast. Science, 2011, 334, 1241-1245.	6.0	345
195	Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 2011, 32, 1207-1218.	1.5	611
196	Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiology of Aging, 2011, 32, S44-S47.	1.5	27
197	Characterizing Alzheimer's disease using a hypometabolic convergence index. NeuroImage, 2011, 56, 52-60.	2.1	144
198	A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1241-1256.	1.2	86

#	Article	IF	Citations
199	Impact of apolipoprotein É›4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. , 2011, 7, 514-520.		26
200	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.4	5,550
201	A method of generating image-derived input function in a quantitative 18F-FDG PET study based on the shape of the input function curve. Nuclear Medicine Communications, 2011, 32, 1121-1127.	0.5	10
202	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
203	CR1 is associated with amyloid plaque burden and ageâ€related cognitive decline. Annals of Neurology, 2011, 69, 560-569.	2.8	148
204	Altered default mode network connectivity in alzheimer's diseaseâ€”A resting functional MRI and bayesian network study. Human Brain Mapping, 2011, 32, 1868-1881.	1.9	172
205	Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-Î² in a Patient With Down Syndrome and Alzheimer Disease. Archives of Neurology, 2011, 68, 1461.	4.9	51
206	Brain effective connectivity modeling for alzheimer's disease by sparse gaussian bayesian network. , 2011, , 931-939.		24
207	Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments. Journal of Alzheimer's Disease, 2011, 26, 321-329.	1.2	309
208	Clinical Impact of Updated Diagnostic and Research Criteria for Alzheimerâ€™s Disease. Journal of Clinical Psychiatry, 2011, 72, e37.	1.1	15
209	Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Research, 2010, 1347, 179-185.	1.1	92
210	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensorâ€based morphometry. Human Brain Mapping, 2010, 31, 499-514.	1.9	66
211	Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. Journal of Neuroscience Methods, 2010, 192, 277-285.	1.3	14
212	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
213	Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE Îµ4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene. Journal of Alzheimer's Disease, 2010, 22, 307-313.	1.2	131
214	Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Molecular Genetics, 2010, 19, 3295-3301.	1.4	223
215	Alzheimerâ€™s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine, 2010, 4, 3-14.	0.6	150
216	Hypometabolism in Alzheimer-Affected Brain Regions in Cognitively Healthy Latino Individuals Carrying the Apolipoprotein E Îµ4 Allele. Archives of Neurology, 2010, 67, 462-8.	4.9	89

#	Article	IF	Citations
217	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.9	376
218	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. NeuroImage, 2010, 51, 63-75.	2.1	79
219	Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage, 2010, 51, 654-664.	2.1	145
220	Reducing modeling error of graphical methods for estimating volume of distribution measurements in PIBâ€“PET study. Mathematical Biosciences, 2010, 226, 134-146.	0.9	4
221	Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiology of Aging, 2010, 31, 549-566.	1.5	68
222	Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiology of Aging, 2010, 31, 901-909.	1.5	100
223	Whole brain atrophy rate predicts progression from MCI to Alzheimerâ€™s disease. Neurobiology of Aging, 2010, 31, 1601-1605.	1.5	45
224	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's and Dementia, 2010, 6, 221-229.	0.4	464
225	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. NeuroImage, 2010, 49, 169-176.	2.1	61
226	Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. NeuroImage, 2010, 50, 935-949.	2.1	280
227	Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 19-30.	0.4	4
228	Fibrillar amyloid-Î² burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6820-6825.	3.3	700
229	Improved application of independent component analysis to functional magnetic resonance imaging study via linear projection techniques. Human Brain Mapping, 2009, 30, 417-431.	1.9	14
230	FDGâ€“PET parametric imaging by total variation minimization. Computerized Medical Imaging and Graphics, 2009, 33, 295-303.	3.5	17
231	Genetic Control of Human Brain Transcript Expression in Alzheimer Disease. American Journal of Human Genetics, 2009, 84, 445-458.	2.6	290
232	Longitudinal Modeling of Age-Related Memory Decline and theAPOEÎµ4 Effect. New England Journal of Medicine, 2009, 361, 255-263.	13.9	469
233	Reanalysis of the Obesity-Related Attenuation in the Left Dorsolateral Prefrontal Cortex Response to a Satiating Meal Using Gyral Regions-of-Interest. Journal of the American College of Nutrition, 2009, 28, 667-673.	1.1	31
234	Sparse Inverse Covariance Analysis of human brain for Alzheimer's disease study. , 2009, , .		2

#	Article	IF	Citations
235	Whole brain atrophy based on iterative principal component analysis and MRI techniques in the study of Alzheimer's disease. , 2009, , .		2
236	Using the Artificial Neural Network to discriminate between normal controls with different APOE e4 genotypes and probable AD cases in PIB-PET studies. , 2009, , .		1
237	Automation of the Logan plot based PiB-PET quantification over multiple subjects and multiple reference regions. , 2009, , .		0
238	Neural correlates of heart rate variability during emotion. NeuroImage, 2009, 44, 213-222.	2.1	588
239	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage, 2009, 45, 1107-1116.	2.1	258
240	Linking functional and structural brain images with multivariate network analyses: A novel application of the partial least square method. NeuroImage, 2009, 47, 602-610.	2.1	65
241	Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. NeuroImage, 2009, 48, 668-681.	2.1	129
242	Peripheral delivery of a ROCK inhibitor improves learning and working memory.. Behavioral Neuroscience, 2009, 123, 218-223.	0.6	89
243	20 Brain Imaging in the Evaluation of Putative Alzheimerâ€™s Disease-Slowing, Risk-Reducing and Prevention Therapies. , 2009, , 319-350.		10
244	Untangling the Roles of Antidepressants and Mood Stabilizers in the Treatment of Alzheimer's Disease. Journal of Clinical Psychiatry, 2009, 70, 913-914.	1.1	1
245	FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. International Journal of Developmental Neuroscience, 2008, 26, 253-258.	0.7	29
246	Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. NeuroImage, 2008, 40, 1214-1221.	2.1	30
247	Association between trait emotional awareness and dorsal anterior cingulate activity during emotion is arousal-dependent. NeuroImage, 2008, 41, 648-655.	2.1	151
248	<i>Sorl1</i> as an Alzheimerâ€™s Disease Predisposition Gene?. Neurodegenerative Diseases, 2008, 5, 60-64.	0.8	73
249	Multicenter Standardized ¹⁸F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. Journal of Nuclear Medicine, 2008, 49, 390-398.	2.8	637
250	Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4441-4446.	3.3	529
251	Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiological Genomics, 2008, 33, 240-256.	1.0	264
252	Correlating Cerebral Hypometabolism With Future Memory Decline in Subsequent Converters to Amnestic Preâ€“Mild Cognitive Impairment. Archives of Neurology, 2008, 65, 1231-6.	4.9	91

#	Article	IF	Citations
253	Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiological Genomics, 2007, 28, 311-322.	1.0	277
254	Cognitive Performance in Older Women Relative to ApoE-Îµ4 Genotype and Aerobic Fitness. Medicine and Science in Sports and Exercise, 2007, 39, 199-207.	0.2	103
255	Cognitive Domain Decline in Healthy Apolipoprotein E Îµ4 Homozygotes Before the Diagnosis of Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1306.	4.9	137
256	Correlations Between Apolipoprotein E Îµ4 Gene Dose and Whole Brain Atrophy Rates. American Journal of Psychiatry, 2007, 164, 916-921.	4.0	104
257	GAB2 Alleles Modify Alzheimer's Risk in APOE É›4 Carriers. Neuron, 2007, 54, 713-720.	3.8	451
258	Relationships between plasma leptin concentrations and human brain structure: A voxel-based morphometric study. Neuroscience Letters, 2007, 412, 248-253.	1.0	72
259	Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage, 2007, 35, 511-517.	2.1	112
260	Identification of the Genetic Basis for Complex Disorders by Use of Pooling-Based Genomewide Single-Nucleotideâ€“Polymorphism Association Studies. American Journal of Human Genetics, 2007, 80, 126-139.	2.6	139
261	Calmodulin-binding transcription activator 1 (CAMTA1) alleles predispose human episodic memory performance. Human Molecular Genetics, 2007, 16, 1469-1477.	1.4	66
262	Less activation in the left dorsolateral prefrontal cortex in the reanalysis of the response to a meal in obese than in lean women and its association with successful weight loss. American Journal of Clinical Nutrition, 2007, 86, 573-579.	2.2	113
263	A survey of genetic human cortical gene expression. Nature Genetics, 2007, 39, 1494-1499.	9.4	488
264	Linking Brain Imaging and Genomics in the Study of Alzheimer's Disease and Aging. Annals of the New York Academy of Sciences, 2007, 1097, 94-113.	1.8	33
265	A High-Density Whole-Genome Association Study Reveals That APOE Is the Major Susceptibility Gene for Sporadic Late-Onset Alzheimer's Disease. Journal of Clinical Psychiatry, 2007, 68, 613-618.	1.1	484
266	Focus on Alzheimer's Disease and Related Disorders: Clinical Trials and Tribulations. Journal of Clinical Psychiatry, 2007, 68, 428-429.	1.1	0
267	Common Kibra Alleles Are Associated with Human Memory Performance. Science, 2006, 314, 475-478.	6.0	391
268	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 6-15.	0.6	203
269	Network analysis of single-subject fMRI during a finger opposition task. NeuroImage, 2006, 32, 325-332.	2.1	35
270	Brain abnormalities in human obesity: A voxel-based morphometric study. NeuroImage, 2006, 31, 1419-1425.	2.1	459

#	Article	IF	Citations
271	Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion, 2006, 6, 194-210.	1.6	41
272	Impaired platelet mitochondrial activity in Alzheimerâ€™s disease and mild cognitive impairment. Mitochondrion, 2006, 6, 323-330.	1.6	152
273	Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1359-1371.	1.5	158
274	A Preliminary Fluorodeoxyglucose Positron Emission Tomography Study in Healthy Adults Reporting Dream-Enactment Behavior. Sleep, 2006, 29, 927-933.	0.6	51
275	Less activation of the left dorsolateral prefrontal cortex in response to a meal: a feature of obesity. American Journal of Clinical Nutrition, 2006, 84, 725-731.	2.2	151
276	Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 225-233.	1.2	21
277	Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice. NeuroReport, 2006, 17, 829-832.	0.6	19
278	Regional network of magnetic resonance imaging gray matter volume in healthy aging. NeuroReport, 2006, 17, 951-956.	0.6	74
279	Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Research, 2006, 1116, 194-200.	1.1	37
280	An automated normative-based fluorodeoxyglucose positron emission tomography image-analysis procedure to aid Alzheimer disease diagnosis using statistical parametric mapping and interactive image display. , 2006, 6144, 1638.		1
281	Arithmetic processing in the brain shaped by cultures. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10775-10780.	3.3	306
282	Genetics, Transcriptomics, and Proteomics of Alzheimers Disease. Journal of Clinical Psychiatry, 2006, 67, 652-670.	1.1	96
283	Focus on Alzheimer's Disease and Related Disorders. Journal of Clinical Psychiatry, 2006, 67, 1782-1783.	1.1	3
284	Alzheimer's Disease A Century Later. Journal of Clinical Psychiatry, 2006, 67, 1784-1800.	1.1	99
285	Cerebral asymmetry in children when reading Chinese characters. Cognitive Brain Research, 2005, 24, 206-214.	3.3	39
286	From The Cover: Correlations between apolipoprotein E Â4 gene dose and brain-imaging measurements of regional hypometabolism. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8299-8302.	3.3	366
287	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
288	Sensory experience of food and obesity: a positron emission tomography study of the brain regions affected by tasting a liquid meal after a prolonged fast. NeuroImage, 2005, 24, 436-443.	2.1	139

#	Article	IF	Citations
289	Focus on Alzheimer's Disease and Related Disorders. Journal of Clinical Psychiatry, 2005, 66, 816-817.	1.1	7
290	The Differential Benefits Of Aerobic Fitness For Cognitive Performance As A Function Of ApoE Genotype. Medicine and Science in Sports and Exercise, 2005, 37, S462-S463.	0.2	1
291	Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 284-289.	3.3	907
292	A Distinctive Interaction Between Chronic Anxiety and Problem Solving in Asymptomatic APOE e4 Homozygotes. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 320-329.	0.9	39
293	An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. NeuroImage, 2004, 22, 134-143.	2.1	48
294	Clustering huge data sets for parametric PET imaging. BioSystems, 2003, 71, 81-92.	0.9	64
295	Apolipoprotein E Îµ4 affects new learning in cognitively normal individuals at risk for Alzheimerâ€™s disease. Neurobiology of Aging, 2003, 24, 947-952.	1.5	66
296	Monte-Carlo based neuroimaging set-level multiple-comparison correction. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 11-15.	0.4	4
297	Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimerâ€™s Disease Treatment Studies. American Journal of Psychiatry, 2002, 159, 738-745.	4.0	437
298	Tasting a liquid meal after a prolonged fast is associated with preferential activation of the left hemisphere. NeuroReport, 2002, 13, 1141-1145.	0.6	39
299	Sex differences in the human brainâ€™s response to hunger and satiation. American Journal of Clinical Nutrition, 2002, 75, 1017-1022.	2.2	120
300	A Distinctive Interaction Between Memory and Chronic Daytime Somnolence in Asymptomatic APOE e4 Homozygotes. Sleep, 2002, 25, 437-443.	0.6	29
301	Apolipoprotein E and Intellectual Achievement. Journal of the American Geriatrics Society, 2002, 50, 49-54.	1.3	13
302	Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography. Annals of the New York Academy of Sciences, 2002, 967, 389-97.	1.8	87
303	Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. Journal of the Neurological Sciences, 2001, 189, 93-98.	0.3	57
304	Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease. NeuroReport, 2001, 12, 2375-2379.	0.6	64
305	Effect of Satiation on Brain Activity in Obese and Lean Women. Obesity, 2001, 9, 676-684.	4.0	184
306	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clinical Neuroscience Research, 2001, 1, 194-206.	0.8	26

#	Article	IF	Citations
307	Tracking AlzheimerÊ¼s disease in transgenic mice using fluorodeoxyglucose autoradiography. NeuroReport, 2000, 11, 987-991.	0.6	63
308	Talkativeness in Cognitively Normal Women at Genetic Risk for Alzheimerâ€™s Disease. Aging, Neuropsychology, and Cognition, 2000, 7, 217-226.	0.7	3
309	Regions of the human brain affected during a liquid-meal taste perception in the fasting state: a positron emission tomography study. American Journal of Clinical Nutrition, 1999, 70, 806-810.	2.2	67
310	Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. Journal of Neurosurgery, 1999, 91, 797-803.	0.9	70
311	Positron Emission Tomography Using [18F] Fluorodeoxyglucose and [11C] L-Methionine to Metabolically Characterize Dysembryoplastic Neuroepithelial Tumors. Journal of Child Neurology, 1999, 14, 673-677.	0.7	25
312	Medial temporal lobe activation during episodic encoding and retrieval: A PET study. , 1999, 9, 575-581.		55
313	Neural Correlates of Levels of Emotional Awareness: Evidence of an Interaction between Emotion and Attention in the Anterior Cingulate Cortex. Journal of Cognitive Neuroscience, 1998, 10, 525-535.	1.1	670
314	Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography, 18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 716-723.	2.4	286
315	Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Annals of Neurology, 1998, 44, 288-291.	2.8	257
316	Effects of size and orientation change on hippocampal activation during episodic recognition. NeuroReport, 1997, 8, 3993-3998.	0.6	41
317	Use of Positron Emission Tomography for Presurgical Localization of Eloquent Brain Areas in Children with Seizures. Pediatric Neurosurgery, 1997, 26, 144-156.	0.4	61
318	Positron Emission Tomography in Children With Neurofibromatosis-1. Journal of Child Neurology, 1997, 12, 499-506.	0.7	37
319	Neuroanatomical correlates of pleasant and unpleasant emotion. Neuropsychologia, 1997, 35, 1437-1444.	0.7	778
320	Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the Îµ4 Allele for Apolipoprotein E. New England Journal of Medicine, 1996, 334, 752-758.	13.9	1,320
321	Neuroanatomical Correlates of Veridical and Illusory Recognition Memory: Evidence from Positron Emission Tomography. Neuron, 1996, 17, 267-274.	3.8	258
322	Brain regions associated with retrieval of structurally coherent visual information. Nature, 1995, 376, 587-590.	13.7	277
323	Enhanced Detection of Focal Brain Responses Using Intersubject Averaging and Change-Distribution Analysis of Subtracted PET Images. Journal of Cerebral Blood Flow and Metabolism, 1988, 8, 642-653.	2.4	468
324	A focal brain abnormality in panic disorder, a severe form of anxiety. Nature, 1984, 310, 683-685.	13.7	315